Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies

PURPOSE: We determined the safety, pharmacokinetics, pharmacodynamics and recommended phase II dose of the base excision repair blocker methoxyamine combined with fludarabine. MATERIALS AND METHODS: This was a phase I study with intravenous fludarabine (25 mg/m(2), days 1–5), and methoxyamine (15 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Caimi, Paolo F., Cooper, Brenda W., William, Basem M., Dowlati, Afshin, Barr, Paul M., Fu, Pingfu, Pink, John, Xu, Yan, Lazarus, Hillard M., de Lima, Marcos, Gerson, Stanton L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668101/
https://www.ncbi.nlm.nih.gov/pubmed/29108368
http://dx.doi.org/10.18632/oncotarget.20094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668101/
https://www.ncbi.nlm.nih.gov/pubmed/29108368
http://dx.doi.org/10.18632/oncotarget.20094

Ejemplares similares